Healthy
Conditions
Keywords
Bioequivalence, Atorvastatin calcium, crossover
Brief summary
The purpose of this study is to assess the bioequivalence between Atorvastatin calcium 40 mg of Dr. Reddy's Laboratories Limited, India and Lipitor® 40mg Tablets of Pfizer Ireland Pharmaceuticals in healthy, adult, human subjects under fed condition.
Detailed description
Open-label, balanced, randomized, two-treatment, two-sequence,two-period, single-dose, crossover oral bioequivalence study of Atorvastatin calcium 40 mg Tablets of Dr. Reddy's Laboratories Limited, India and Lipitor® 40 mg Tablets of Pfizer Ireland Pharmaceuticals in healthy, adult, human subjects under fed conditions.
Interventions
Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
Sponsors
Dr. Reddy's Laboratories Limited
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Subjects aged between 18 and 45 years (both inclusive) 2. Subjects' weight within normal range according to normal values for Body Mass Index (18.5 to 24.9 kg/m2)with minimum of 50 kg weight. 3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations within the clinically acceptable reference range. 4. Subjects having normal 12-lead electrocardiogram (ECG). 5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period 01. 6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine)/ 7. Subjects having negative alcohol breath test. 8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.
Exclusion criteria
The subjects were excluded from the study, if they meet any of the following criteria: 1. Hypersensitivity to Atorvastatin or related class of drugs. 2. History of presence of significant cardiovascular, pulmonary, hepatic,renal, gastrointestinal, endocrine, immunological,dermatological, neurological or psychiatric disease or disorder. 3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting. 4. History or presence of significant alcoholism or drug abuse in the past one year. 5. History or presence of significant smoking (more than 10 cigarettes of beedi's/day). 6. History or presence of asthma, urticaria or other significant allergic reactions. 7. History or presence of significant gastric and/or duodenal ulceration. 8. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor. 9. History or presence of cancer. 10. Difficulty with donating blood. 11. Difficulty in swallowing solids like tablets or capsules. 12. Use of any prescribed or OTC medication during last two weeks prior to dosing in period 01. 13. Major illness during 3 months before screening. 14. Participation in a drug research study within past 3 months. 15. Donation of blood in the past 3 months before screening. 16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing. 17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C. 18. History or presence of significant easy bruising or bleeding. 19. History or presence of significant recent trauma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under curve (AUC) | Pre-dose at 0.00 hour and post dose at 0.25, 0.50, 0.75,1.00, 1.25, 1.50, 1.75,2.00,2.25,2.50,2.75,3.00,3.33,3.67,4.00,4.50, 5.00, 6.00,8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours |
Countries
India
Outcome results
None listed